| Mrs Marie Louise Joris, PT | |
|
Unit 21414 Box 3530, Shape Healthcare Facility, Apo, AE 09705-1414 | |
| (003) 265-445892 | |
| (003) 265-445919 |
| Full Name | Mrs Marie Louise Joris |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | Unit 21414 Box 3530, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134439250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 51022790512 (ZZ) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Marie Louise Joris, PT 457 Chemin De Mormal, Mecquignies, FRANCE 59570 Ph: (003) 332-7638286 | Mrs Marie Louise Joris, PT Unit 21414 Box 3530, Shape Healthcare Facility, Apo, AE 09705-1414 Ph: (003) 265-445892 |
News Archive
New research has shown that many young Australians are not having their wishes to donate their organs honored because they fail to discuss these issues with their families beforehand. As a remedial measure Australia's chief medical officer, Professor Jim Bishop has urged more of the young population to come forth about their wishes to donate their organs after death.
Children who suffer from intestinal failure, most often caused by a shortened or dysfunctional bowel, are unable to consume food orally. Instead, a nutritional cocktail of sugar, protein and fat made from soybean oil is injected through a small tube in their vein.
Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.
The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced an expansion of its partnership with the Children's Tumor Foundation to create unique neurofibromatosis (NF) pathway maps aimed at significantly increasing the understanding of the disease and its underlying mechanisms.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
› Verified 3 days ago
Joseph Frjelich, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Hq Meddac Bavaria, Unit 28037 Bldg 700, Apo, AE 09112 Phone: 314-590-2368 | |
Emily Ward, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Usahc Vicenza, Apo, AE 09630 Phone: 339-619-7896 | |
Jenna Marie Boyd, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 3215, Apo, AE 09094 Phone: 314-479-2609 | |
Dr. Ashlyn Owens Hull, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: U.s. Army Health Clinic Hohenfels Unit 28216 Hohenfels,, Apo, AE 09173 Phone: 314-590-3300 | |
Maria Lebron, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 94, Apo, AE 09824 Phone: 011-903-163223380 | |
Dr. Nicoleta Grigoras, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 33100, Apo, AE 09180 Phone: 314-590-8298 | |
Susan Kay Oppliger, PHYSICAL THERAPIST Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Attn:mceul-dccs (credentials), Apo, AE 09180 Phone: 011-496-78366710 |